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Type I Interferon Rapidly Restricts Infectious
Hepatitis C Virus Particle Genesis
Luke W. Meredith,1 Michelle J. Farquhar,1 Alexander W. Tarr,2 and Jane A. McKeating1,3
Interferon-alpha (IFNa) has been used to treat chronic hepatitis C virus (HCV) infec-
tion for over 20 years with varying efficacy, depending on the infecting viral genotype.
The mechanism of action of IFNa is not fully understood, but is thought to target mul-
tiple stages of the HCV lifecycle, inhibiting viral transcription and translation leading
to a degradation of viral RNA and protein expression in the infected cell. IFNa induces
the expression of an array of interferon-stimulated genes within minutes of receptor
engagement; however, the impact of these early responses on the viral lifecycle are
unknown. We demonstrate that IFNa inhibits the genesis of infectious extracellular
HCV particles within 2 hours of treating infected cells, with minimal effect on the intra-
cellular viral burden. Importantly, this short duration of IFNa treatment of infected
cells significantly reduced cell-free and cell-to-cell dissemination. The secreted viral par-
ticles showed no apparent change in protein content or density, demonstrating that
IFNa inhibits particle infectivity but not secretion rates. To investigate whether particles
released from IFNa-treated cells have a reduced capacity to establish infection we used
HCV lentiviral pseudotypes (HCVpp) and demonstrated a defect in cell entry. Using a
panel of monoclonal antibodies targeting the E2 glycoprotein, we demonstrate that
IFNa alters glycoprotein conformation and receptor utilization. Conclusion: These
observations show a previously unreported and rapid effect of IFNa on HCV particle
infectivity that inhibits de novo infection events. Evasion of this response may be a con-
tributing factor in whether a patient achieves early or rapid virological response, a key
indicator of progression to sustained virological response or clearance of viral infection.
(HEPATOLOGY 2014;60:1891-1901)
H
epatitis C virus (HCV) infection is a major
cause of chronic liver disease that affects 170
million people worldwide, leading to cirrhosis
and hepatocellular carcinoma. For many years the only
available therapy was pegylated type I interferon alpha
(IFNa) and ribavirin that cured less than 50% of cases
in a genotype-dependent manner, prompting the devel-
opment of direct-acting antiviral agents (DAAs) target-
ing the viral replicase.1 The approval of HCV protease
and polymerase inhibitors and combination treatment
with IFN has led to a significant increase in patient
response rates, providing a new standard of care.2
Type I IFN stimulates the expression of a number of
interferon-stimulated genes (ISGs) that inhibit HCV
genome translation and replication3,4 and protect neigh-
boring uninfected cells from viral infection. Once IFN
pathways are activated the downstream response has enor-
mous breadth, as noted by the many hundreds of ISGs.
In a recent screen 380 ISGs were tested for their ability
to inhibit genotype 2a HCV replication and at least 25
genes were identified that reduced viral replication.5 Zhao
et al.6 reported that silencing 60 ISGs prior to IFN treat-
ment revealed no individual gene knockdown that could
rescue the inhibitory effect of IFN on HCV replication.
This finding is consistent with the widely accepted
hypothesis that the IFN system works in a combinatorial
fashion, with multiple ISGs contributing to antiviral
responses with no single ISG serving as a “magic bullet.”
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Mathematical modeling of HCV replication kinetics
following treatment has provided valuable insights into
the mechanism of action of antiviral agents.7,8 HCV
RNA declines in a biphasic pattern after IFN therapy,
with the initial phase representing a decrease in viral pro-
duction from infected cells, while the slower and more
variable phase is attributed to the loss of infected cells by
way of the stimulated immune system. Importantly, there
are multiple outcomes observed following IFN therapy,
including rapid, partial, and nonresponse, where a rapid
virological response is frequently associated with a cure
even more than the commonly used IL-28B polymor-
phisms.9 Recent modeling studies suggest that for maxi-
mal efficacy IFN needs to inhibit infectious virus
production and de novo transmission events.10,11 However,
the majority of reports studying the impact of IFN on
HCV replication have not analyzed these steps in the viral
lifecycle.
Reports of IFN-mediated signaling generally study
cellular responses within minutes of receptor engage-
ment. However, studies investigating the antiviral
effects of IFN measure HCV RNA and proteins sev-
eral days posttreatment. We demonstrate that treating
HCV-infected Huh-7 cells with IFNa for 1 hour
reduces the infectivity of extracellular particles with no
detectable effect on particle secretion. We failed to
detect soluble antiviral effectors released from IFN-
treated cells and purified particles show reduced infec-
tivity, demonstrating a direct effect of IFNa on extrac-
ellular HCV particles. Studies with lentiviral HCV
pseudoparticles (HCVpp) demonstrate that IFN alters
E2 glycoprotein conformation that limits receptor-
dependent internalization. This is the first report of
such a rapid and direct effect of IFNa to reduce parti-
cle specific infectivity in the absence of any detectable
impact on viral RNA load, raising questions on the
interpretation of early phase IFN responses that are
solely based on viral RNA measurements.
Materials and Methods
Cell Lines and Antibodies. Huh-7 or Huh-7.5
cells were propagated in Dulbecco’s modified Eagle’s
medium (DMEM) / 10% fetal bovine serum and 1%
nonessential amino acids. Anti-CD81 2s131 and anti-
SR-BI (gift from Pfizer) were previously reported.30 A
panel of rodent31 and human monoclonal antibodies
(mAbs) mapping to linear or conformation-dependent
HCV E2 epitopes were previously reported.32,33
Immunoglobulin was isolated from the sera of normal
or chronically infected HCV patients by protein G-
conjugated Sepharose beads as previously reported.12
ISG Analysis. HCV-infected cells were treated with
IFNa and cellular RNA extracted using RNAeasy Mini-
prep Kits (Qiagen). ISG expression was quantified using
the Human Interferon Response PCR Array and analyzed
using RT2 Profiler Analysis software (SABiosciences).
Sodium Dodecyl Sulfate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and Western Blotting.
Cells were harvested in lysis buffer containing protease
inhibitors, clarified by centrifugation (20,000g, 10
minutes), and protein concentration quantified by
BCA (Pierce). Normalized protein lysates or virus pel-
lets resuspended in Laemmli buffer were separated by
SDS-PAGE, transferred to PVDF membranes, and
probed for HCV-E2 (mAb 3/11) or HCV-Core (mAb
C750, Thermo Scientific) and expression quantified by
enhanced chemiluminescence and densitometric analy-
sis using ImageJ software.
HCVcc Infectivity, Density Analysis, and Trans-
mission Assay. Plasmids encoding HCV SA13/JFH,
J6/JFH, or H77/JFH were used to generate RNA and
electroporated into Huh-7.5 cells.12 IFNa was added
to cells for defined time periods followed by thorough
washing and harvesting of extracellular media. Infected
cells were fixed with paraformaldehyde, stained for
viral antigen expression with mAbs specific for NS5A
(9E10), Core (C750), or E2 glycoprotein (9/75, 3/11,
6/53) and isotype-matched Alexa-488 conjugated IgG.
Viral antigen expressing cells were enumerated by
fluorescent-activated cell sorter (FACS) and protein
expression assessed by measuring mean fluorescent
intensity (MFI). Extracellular media was collected,
concentrated through 100,000 MWCO concentrators
(Sartorius), loaded onto 10-60% Iodixanol gradients,
and centrifuged at 100,000g for 16 hours at 4C.
Fractions were collected and density assessed by
weight, infectivity by inoculating na€ıve Huh-7.5 cells,
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and HCV RNA by quantitative reverse-transcription
polymerase chain reaction (qRT-PCR).
HCV-infected cells were labeled with fluorescent
cell-tracker CMFDA and cocultured with an equal
number of na€ıve Huh-7 cells at 2.5 3 104 cells/cm2.
Extracellular virus is neutralized with anti-HCV Ig or
control Ig (150 lg/mL) and transmission stopped at
indicated times by anti-CD81 (2s131, 10 lg/mL).12
Cells were harvested and culture media analyzed for
infectious virus, expressed as the number of focus-
forming units (FFU)/mL. Newly infected target cells
were identified by staining for HCV NS5A and quan-
tified by flow cytometry.
HCVpp Infectivity, Glycoprotein Conformation,
and Neutralization. Luciferase reporter pseudopar-
ticles expressing HCV envelope glycoproteins (HCVpp),
or no-glycoprotein controls, were generated in 293T
cells as previously reported.31 HCVpp-293T producer
cells were treated with IFNa for 1 hour, unbound IFN
removed, and the cells incubated for 1 hour prior to
collecting extracellular media to measure infectious
HCVpp and staining cells for E2 expression and quan-
tification by flow cytometry. All anti-E2 mAbs were
used at subsaturating concentrations. HCVpp stocks
were incubated with anti-E2 mAbs or polyclonal anti-
HCV Ig for 1 hour prior to infecting Huh-7.5 cells.
Receptor neutralization was performed by adding anti-
SR-BI, anti-CD81, or isotype control antibody to Huh-
7.5 cells for 1 hour prior to infection.
HCV E2 expression in p24 normalized HCVpp con-
taining supernatants was determined by enzyme-linked
immunosorbent assay (ELISA). Briefly, Immulon plates
(Thermo) were coated with GNA (Sigma, UK) and
empigen-lysed HCVpp preparations added for 2 hours
at room temperature. Bound E2 was detected with a
panel of anti-E2 antibodies and HRP-conjugated anti-
rat Ig. For HIV-1 p24 quantification, MaxiSorp plates
(Nalge Nunc) coated with anti-p24 antibody D7324
were used to capture HCVpp (0.5% Tween-20 / 0.1%
casein / 1.44M NaCl / 250 mM Tris-Cl, pH 7.5) and
bound antigen detected with biotinylated rabbit anti-
p24 and streptavidin-HRP (BD Pharmingen). Bound
HRP-conjugates were quantified colorimetrically after
reaction with a TMB substrate (BioFX).
Results
IFNa Rapidly Induces an Antiviral State. While
the clinical impact of IFN therapy on HCV replication
kinetics has been extensively studied, our understanding
of early IFN-signaling events in the virus lifecycle is
limited. Using a commercial IFN-selected PCR array,
we confirmed a significant induction of multiple ISGs
within 1 hour of treating HCV-infected Huh-7 cells
with IFNa (Fig. 1A). To assess whether this early
response has an impact on virus replication, infected
cells were treated with varying doses of IFNa for 1
hour and virus infectivity measured. The treated cells
were washed extensively to remove exogenous IFNa
prior to harvesting samples to ensure minimal carryover
when measuring viral infectivity. We noted a dose-
dependent decrease in extracellular infectivity with no
observable effect on the intracellular pool of infectious
virus (Fig. 1B). Importantly, the infectivity of extracellu-
lar virus harvested from IFN-treated cells was not
restored by pretreating Huh-7 cells with Jak/Stat inhibi-
tor (InSolution JAK Inhibitor 1) (Fig. 1B). Extracellular
media from IFN-treated Huh-7 cells had no detectable
antiviral activity, suggesting a lack of soluble antiviral
factors. To investigate whether IFN affects particle infec-
tivity, we purified the extracellular virus by ultracentrifu-
gation and demonstrated a significant reduction in the
infectivity of particles (Fig. 1C). In parallel, the superna-
tant from ultracentrifuged IFN-treated samples had no
effect on HCV infection of na€ıve Huh-7.5 cells (Fig.
1D), demonstrating that IFN reduces HCV particle
infectivity. Finally, we demonstrated that IFN reduces
the level of extracellular infectious virus of chimeric
strains expressing genotype 1 (H77), genotype 2 (J6), or
genotype 5 (SA13) structural proteins (Fig. 1E).
The observation that IFNa reduces extracellular
HCV infectivity could be explained by the reduced
secretion of particles and/or a loss in particle infectivity.
To determine whether IFNa affects HCV particle secre-
tion we measured viral-encoded core, envelope glyco-
protein E2, and genomic RNA levels in infected cells
and in purified extracellular particles. This short-term
IFNa treatment had no detectable effect on intracellular
or extracellular particulate viral protein (Fig. 2A) or
RNA expression (Fig. 2B), suggesting that IFNa has
minimal effects on virus secretion. HCV assembly is
dependent on the VLDL pathway and extracellular lipo-
viral particle infectivity has been reported to associate
with particle density. IFNa had minimal impact on
HCV particle density, with untreated particles showing
a peak of infectious virus at a density of 1.09 g/L com-
pared to 1.08 g/L for IFNa-treated cells and no signifi-
cant change in viral RNA levels (Fig. 2C). In summary,
these results show that IFNa reduces the infectivity of
extracellular HCV particle while having minimal impact
on secretion or particle density.
IFNa Rapidly Prevents De Novo HCV Infec-
tion. To investigate the impact of this rapid IFN-
mediated response on infectious particle genesis on viral
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Fig. 1. IFNa rapidly reduces extracellular virus infectivity. HCV (SA13/JFH)-infected Huh-7.5 cells were treated with IFNa (1,000 IU/mL) for 1
hour, cellular RNA extracted, and analyzed in a selected mRNA IFN PCR array. Results show the fold regulation of 64 ISGs in infected cells com-
pared to untreated (A). HCV strain SA13/JFH-infected Huh-7.5 cells were treated with an increasing dose of IFNa for 1 hour, washed thoroughly,
incubated for a further 1 hour prior to collecting extracellular media and cellular lysates to measure infectious virus by inoculating na€ıve Huh-7/5
targets. Huh-7.5 targets were treated with Jak/Stat inhibitor (InSolution JAK Inhibitor 1, 10 lM) for 1 hour prior to infecting with virus harvested
from cells treated with the highest dose of IFNa (B). Virus was purified from the extracellular media by ultracentrifugation through 20% sucrose,
infectivity measured in the presence or absence of Jak/Stat inhibitor (C) and the antiviral activity of the clarified supernatant assessed by pretreating
Huh-7.5 cells for 2 hours prior to infecting with HCVcc (D). The effect of IFNa (1,000 IU/mL, 1-hour treatment) on extracellular infectious virus
released from H77/JFH, J6/JFH, and SA13/JFH infected Huh-7.5 cells (E). Results shown are the mean and standard deviation of three experi-
ments, and significance calculated using Student t tests (*P< 0.05, **P< 0.01, ***P< 0.005) comparing treated sample to untreated controls.
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Fig. 2. IFNa does not perturb HCV particle composition or density. HCV (SA13/JFH)-infected Huh-7.5 cells were treated with IFNa (1,000 IU/
mL) for 1 hour, washed thoroughly, and the extracellular media collected for a further 1 hour. HCV Core and E2 expression in extracellular puri-
fied virus and cell lysates was assessed by western blot and densitometric imaging (expressed in arbitrary light units, ALU) (A) while HCV RNA
was quantified by qRT-PCR (B). The lipid density of the treated and untreated virus was assessed using 10-60% Iodixanol gradient centrifugation:
the graphs depict the infectivity, HCV RNA, and density of each fraction from IFN-treated or untreated cells (C).
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dissemination, we used a recently developed single-cycle
infection assay that quantifies de novo infection events.12
This assay uses the neutralizing capacity of anti-HCV
Ig to limit extracellular virus infectivity to discriminate
between cell-free and cell-to-cell infection events. Thus,
we were able to study the temporal effect(s) of IFNa on
HCV-infected cells and to discriminate from bystander
effects on na€ıve cells. HCV SA13/JFH infected Huh-
7.5 cells were treated for 1 hour with IFNa (1,000 IU/
mL), washed thoroughly to remove exogenous IFN,
and labeled with CMFDA prior to coculturing with
na€ıve Huh-7.5 cells in the presence or absence of neu-
tralizing anti-HCV Ig. At indicated timepoints, viral
dissemination was stopped by adding an antibody tar-
geting the CD81 receptor (2s131, 10 lg/mL), then
incubated for a further 24 hours prior to harvesting
cells for flow cytometric detection of newly infected tar-
get cells (NS5A1/CMFDA-) and collection of extracel-
lular media to measure virus infectivity.
As expected, we noted significant reductions in the
level of extracellular infectious virus in the IFN-treated
samples at all timepoints (Fig. 3A). IFNa treatment of
infected cells for 1 hour significantly reduced cell-free
and cell-to-cell dissemination routes within the first 2
hours of coculture and this effect was maintained for
the duration of the assay (Fig. 3B). We noted a mini-
mal effect of IFNa on the expression of HCV Core or
NS5A in infected cells within the first 8 hours follow-
ing treatment (Fig. 3C). These observations highlight
a new role for IFN to limit the genesis of infectious
HCV particles and inhibit de novo transmission events.
IFNa Perturbs HCV Glycoprotein-Dependent
Particle Infectivity. To ascertain whether HCV par-
ticles released from IFNa-treated cells are defective at
Fig. 3. IFNa inhibits cell-free and cell-to-cell HCV transmission. HCV (SA13/JFH)-infected Huh-7.5 cells were treated with IFNa (1,000 IU/mL)
for 1 hour, washed thoroughly to remove IFNa, labeled with CMFDA, and cocultured with na€ıve Huh-7.5 cells. One hour post-coculture anti-HCV
Ig was added to neutralize extracellular virus and at indicated timepoints anti-CD81 was added to block all subsequent transmission events.
Twenty-four hours post-coculture the levels of the infectious virus in the extracellular media were measured (A) and de novo infection events
determined by flow cytometry (B). The results represent the mean and standard deviation of three experiments, and significance calculated using
Student t tests (*P< 0.05, **P< 0.01, ***P< 0.005) comparing treated sample to untreated controls. To assess whether IFNa induced any
viral protein degradation during this time period, CMFDA-labeled infected cells were stained for HCV Core or NS5A (C) and the data presented
as mean fluorescent intensity (MFI).
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entering target cells, we used lentiviral pseudoviruses
expressing HCV glycoproteins to measure the impact
of IFNa on receptor-dependent particle entry. HCVpp
(strain H77)-expressing cells were treated with IFNa
(1,000 IU/mL) for 1 hour, washed thoroughly, and
extracellular media collected to quantify viral infectiv-
ity. As controls, we evaluated the effect of IFNa on
the infectivity of pseudoviruses expressing Lassa virus
and Murine Leukemia virus (MLV) envelope glycopro-
teins. IFNa reduced the infectivity of HCVpp by 60%
but had minimal effect on Lassa or MLVpp infectivity
(Fig. 4A). Importantly, IFNa had no detectable effect
on the level of HCVpp-incorporated E2 glycoprotein
(Fig. 4B), suggesting a similar phenotype to that
observed for HCVcc, where intact pseudoparticles are
released but are unable to enter cells. To assess the
Fig. 4. IFNa-treated HCVpp show defective entry and increased sensitivity to anti-SR-BI neutralization. 293T cells expressing pseudoparticles con-
taining the indicated viral envelopes were treated with IFNa (1,000 IU/mL) for 1 hour, washed thoroughly, incubated for 1 hour, and the extracellular
media collected and used to inoculate na€ıve Huh-7.5 cells (A). The levels of HCVpp-H77 associated E2 were measured on p24-normalized particle
preparations by ELISA (B). The effect of IFNa (1,000 IU/mL, 1 hour) on the infectivity of HCVpp expressing a range of genotype 1 glycoproteins (C).
HCVpp-H77 were allowed to infect Huh-7.5 cells preincubated for 1 hour with anti-SR-BI (D) or anti-CD81 (E) and infection assessed 72 hours later
by measuring luciferase activity. Results are the mean and standard deviation of three assays with duplicate samples where the significance of dif-
ferences between sensitivities to neutralization at each timepoint was assessed using paired t tests (*P< 0.05, **P< 0.01, ***P< 0.005). IFNa
had comparable effects on the sensitivity of HCVcc (H77/JFH) to neutralization by anti-SR-BI. Data are presented as IC50 values (F).
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Fig. 5. IFNa perturbs HCV glycoprotein conformation. HCVpp-H77 producer 293T cells were treated with IFNa (1,000 IU/mL) for 1 hour,
washed thoroughly, incubated for a further hour, and the reactivity of a panel of mAbs targeting linear E1E2 epitopes or a control polyclonal
anti-HCV Ig to cell surface expressed antigen or extracellular HCVpp measured by flow cytometry or ELISA, respectively (A). A panel of human
antibodies targeting conformation-dependent E2 epitopes (1 lg/mL) were tested for their ability to bind HCVpp-H77-expressing 293T cells or to
neutralize extracellular virus following IFNa (1,000 IU/mL, 1 hour) treatment (B). Human antibody anti-E2 (1 lg/mL) neutralization of HCVcc
(H77-JFH) released from IFNa (1,000 IU/mL, 1 hour) treated or untreated cells (C). Results are the mean and standard deviation of three experi-
ments and significance was calculated using paired t tests (*P< 0.05, **P< 0.01, ***P< 0.005).
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breadth of this phenotype we assessed the impact of
IFNa treatment on the infectivity of pseudoparticles
expressing a panel of genotype 1 HCV glycoproteins.
Of note, five of the 10 envelopes showed a significant
reduction in particle infectivity, whereas IFNa had no
effect on the infectivity of the remaining pseudoparticles
(Fig. 4C). We next investigated the receptor usage of
HCVpp released from IFNa-treated or untreated cells.
HCVpp-H77 released from IFNa-treated cells showed
an increased sensitivity to neutralization by anti-SR-BI,
showing an median inhibitory concentration (IC50) of
0.06 lg/mL compared to 0.9 lg/mL for untreated
virus, but no change to anti-CD81 (Fig. 4D,E), sug-
gesting that virus released from IFN-treated cells had a
reduced dependency on SR-BI for entry. We observed a
similar reduction in the sensitivity of HCVcc (H77/
JFH) released from IFN-treated cells to neutralization
by anti-SR-BI (Fig. 4F).
IFNa Alters HCV E2 Glycoprotein Conforma-
tion. Since SR-BI has been reported to bind anti-
genic region A13 of E2 glycoprotein, including the
hypervariable region 1 (HVR1), these results suggest
that IFN may promote conformational changes within
the glycoprotein. To test this hypothesis we evaluated
the effect of IFNa on the reactivity of a panel of anti-
bodies targeting linear and conformation-dependent
E2 epitopes. Anti-E2 antibodies were assessed for their
ability to bind IFNa-treated or untreated HCVpp-
producer cells by flow cytometry or to bind extracellu-
lar HCVpp by ELISA. IFNa reduced the binding of
antibodies targeting HVR1 and region A (6/16, 6/
82A, 9/86A, 2/69A), region B (7/16B, 6/1A), but had
no significant effect on those binding region C (Fig.
5A). Further studies with a number of human anti-E2
antibodies showed that IFNa reduced the binding and
neutralizing activity of antibody AR2A that recognizes
a conformation-dependent epitope for HCVpp (Fig.
5B). We confirmed that IFN reduced the sensitivity of
HCVcc (H77/JFH) to neutralization by AR2A and
had modest effects on AR1A and L1 neutralization
(Fig. 5C). Given the low levels of glycoprotein expres-
sion at the surface of HCVcc-infected cells, we were
unable to evaluate antibody binding to the infected
cell surface. The results confirm that IFNa induces a
conformational change in the viral E2 glycoprotein
that limits particle entry.
Discussion
We show that IFNa induces a rapid response in
HCV-infected hepatoma cells that limits the genesis of
infectious extracellular particles with minimal effect on
the intracellular viral burden. This short 2-hour dura-
tion of IFN treatment significantly reduced de novo
transmission events, including cell-free and cell-cell
dissemination. There was limited evidence for IFN-
dependent cellular retention of infectious particles,
consistent with a previous report that tetherin, an
interferon-stimulated protein, has minimal impact on
HCV infectivity.14 Previous studies reported that IFNa
reduced viral RNA and protein expression in HCV-
infected Huh-7 cells or those supporting HCV repli-
cons within 12-16 hours.4,15 However, our studies
focus on the first 2 hours following IFN treatment,
highlighting a new role for IFN to limit particle infec-
tivity prior to reducing viral RNA and protein expres-
sion. Given the difficulties in measuring the infectivity
of primary HCV strains, clinical studies measuring
IFN efficacy rely on genomic RNA measurements and
may underscore the impact of early IFN doses. A
recent model of HCV replication kinetics that meas-
ured intracellular RNA and infectivity concluded that
the NS5A inhibitor daclatasvir has two modes of
action: to block viral RNA synthesis and virion assem-
bly/secretion.16 The authors commented that analysis
of HCV kinetic data following IFNa treatment with
this new model suggested that IFNa reduces HCV
assembly/secretion in addition to its role in slowing
intracellular HCV RNA replication. Our data are con-
sistent with this interpretation and highlights the
importance of studying particle infectivity, i.e., the
ratio of particle infectivity to genomic RNA, allowing
one to discriminate the effect of drugs on virus assem-
bly, secretion, and infectivity.
Our recently published single-cycle infection assay12
enabled us to assess the “early” effects of IFNa on
HCV dissemination. By using a short treatment time
targeted specifically at infected cells, we demonstrate
that IFNa inhibits both cell-free and cell-cell dissemi-
nation routes. We confirmed that this effect on particle
infectivity and transmission occurred significantly ear-
lier than degradation of viral proteins and is not
explained by secreted antiviral factors. Since HCV is a
lipid-rich particle that depends on the very low density
lipoprotein (VLDL) secretion machinery for assembly
and secretion,17,18 we assessed the density of viral par-
ticles released from IFNa-treated cells and saw no
obvious changes in particle density. IFNa treatment
had no significant impact on the level of viral-
associated core or E2 glycoprotein, demonstrating that
intact lipoviral particles with reduced infectivity are
secreted from IFN-treated cells.
The HCVpp system measures glycoprotein-
dependent entry and enabled us to address the role of
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IFNa on the virus internalization process. IFN treat-
ment of HCVpp 293T producer cells reduced the
infectivity of extracellular virus with minimal effect on
E2 incorporation into particles. Previous reports have
shown that IFNa inhibits HIV-1 particle infectivity by
reducing gp120 incorporation into the nascent par-
ticles19; however, this is unlikely to explain the effect
of IFNa on HCVpp infectivity. IFNa had no detecta-
ble effect on the infectivity of pseudoviruses expressing
MLV or Lassa envelopes, suggesting that this effect is
specific to HCV. It is interesting to note the varying
effect of IFNa on the infectivity of pseudoparticles
expressing a panel of genotype 1 patient-derived
clones. HCVpp and HCVcc released from IFNa-
treated cells showed an increased sensitivity to the neu-
tralizing activity of an antibody targeting the cellular
receptor SR-BI but not CD81, suggesting that IFNa
modulates E2 glycoprotein conformation and this may
affect receptor utilization and particle entry. Previous
studies have shown that region A-HVR of the viral E2
glycoprotein binds SR-BI20-22; we therefore used a
panel of mAbs targeting linear and conformational E2
epitopes to study the effect of IFNa on glycoprotein
conformation. We noted significant differences in the
ability of several mAbs recognizing linear and a
conformation-dependent epitope (AR2A) to bind viral
glycoproteins or to neutralize virus infectivity following
IFNa treatment.
This phenotype is comparable to reports showing
that treatment of HCV-infected cells with glycosidase
inhibitors led to the incorporation of misfolded gly-
coproteins into nascent particles.23,24 However, glyco-
sidase inhibitors reduced the infectivity of
intracellular and extracellular HCV, while IFN only
reduced extracellular virus infectivity, suggesting that
HCV glycoproteins undergo a late maturation step
that is required for maximal particle infectivity.25,26
Maturation of HIV-1 glycoproteins has been shown
to “mask” neutralizing epitopes behind a glycan
shield,27,28 and recent studies suggest a similar model
for HCV. Glycosylation plays an important role in
defining E2 conformation, with up to eight glycan
sites reported to be critical for protein folding.29 We
failed to detect any significant change in the mobility
of virion associated E2 from IFN-treated virus by
SDS-PAGE or sensitivity to glycosidase inhibitors
(data not shown), suggesting that IFNa-mediated
effects on HCV E2 conformation are not glycan-
specific.
The results shown here have a particular significance
as therapies move to IFN-free regimens of DAAs such
as protease and polymerase inhibitors. The ability of
IFNa to prevent cell-free and cell-to-cell spread may
contribute to the efficacy of IFN in responsive
patients. Entry inhibitors have long been suggested as
useful adjunct therapies to current treatments, as they
would significantly impair virus dissemination and aid
the clearance of infected cells. It is possible that short
treatments with IFNa may continue to play a signifi-
cant role in patients treated with DAAs, by preventing
viral dissemination.
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